Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.

Quality of care for heart patients does not improve in first year of ACO participation
Researchers tracked patient outcomes through the use of 15 performance measures related to hypertension, coronary artery disease, heart failure and atrial fibrillation.
Key takeaways from ACC.25: Advances in cardiovascular science
Former American College of Cardiology president Hadley Wilson, MD, executive vice chair of Atrium Health Sanger Heart and Vascular Institute, explains his main takeaway messages from the ACC 2025 late-breaking trials.
Dapagliflozin improves outcomes for elderly TAVR patients with heart failure
The positive data were presented as part of a late-breaking clinical trial at ACC.25 in Chicago. One cardiologist on stage for the presentation said these findings will impact the way he manages certain TAVR patients.
Oral semaglutide reduces heart risks while helping patients move past ‘fear of the needle’
Researchers still think patients should receive an injectable version of semaglutide when possible, but new data out of ACC.25 confirm that an oral formulation of the drug is associated with significant benefits.
‘A practice-changing trial’: Semaglutide linked to key benefits for PAD patients with diabetes
Patients who present with type 2 diabetes and PAD often face substantial mobility issues. According to new data presented at ACC.25, however, treatment with semaglutide could represent a major step forward for this high-risk population.

Statin reduces risk for non-obstructive CAD patients but no significant risk reduction for aspirin

The results of a study published in Radiology: Cardiothoracic Imaging call into question the value of initiating aspirin therapy in certain instances.

USPSTF updates its stance on aspirin use to prevent CVD, sees no benefit for patients 60 or older

These recommendations, the group emphasized, do not include patients with a history of CVD or those who are already taking aspirin for another reason.

FDA announces another recall of common hypertension medication due to potential cancer risk

The new recall includes five lots of medications distributed from December 2019 to April 2022. Similar products were also recalled back in March for the same reason.

FDA announces new insulin recall due to potential labeling issue

The recall is focused on a single batch distributed from December 2021 to March 2022.

Steven Nissen, MD, Cleveland Clinic, explains an ACC.22 late-breaking trials that uses an mRNA drug to greatly reduce lipoprotein A. #ACC22

VIDEO: Use of mRNA drug to lower lipoprotein(a) by up to 98%

Steven E. Nissen, MD, chief academic officer of the Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute at the Cleveland Clinic, was the lead author on the Apollo Trial, a late-breaking ACC.22 study evaluating the effectiveness of an mRNA drug to suppress lipoprotein(a).

Older LAAO patients, especially women, face a higher risk of complications

Researchers explored data from the National Inpatient Sample, sharing their findings in the American Journal of Cardiology.

DOACs an effective substitute for VKAs after AFib patients undergo bioprosthetic valve replacement

Direct oral anticoagulants are noninferior to vitamin K antagonists when treating this important patient population, researchers reported.

Evolocumab limits adverse cardiovascular outcomes among PCI patients

Data from the FOURIER trial helped clinicians learn more about this popular PCSK9 inhibitor.

Pharmaceutics

Quality of care for heart patients does not improve in first year of ACO participation

Key takeaways from ACC.25: Advances in cardiovascular science

Dapagliflozin improves outcomes for elderly TAVR patients with heart failure

Oral semaglutide reduces heart risks while helping patients move past ‘fear of the needle’

‘A practice-changing trial’: Semaglutide linked to key benefits for PAD patients with diabetes